Mendus AB (OSTO:IMMU) Other Financing: kr47.66 Mil (TTM As of Mar. 2026)


OSTO:IMMU Mendus AB OSTO:IMMU
27 GF Score
Price kr6.11
! 2 Warning Signs
View Full Analysis

What is Mendus AB Other Financing?

Mendus AB OSTO:IMMU +2.52% 27 Other Financing is kr47.66 Mil as of Mar. 2026. GuruFocus rates OSTO:IMMU with a GF Score™ of 27/100. The stock has 2 warning signs investors should review.

Mendus AB's Other Financing for the three months ended in Mar. 2026 was kr-0.41 Mil.

Mendus AB's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was kr47.66 Mil.

Mendus AB Other Financing Historical Data

* Premium members only.

The historical data trend for Mendus AB's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mendus AB Other Financing Chart

Mendus AB Annual Data
Trend Jun16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.29 0.00 -23.89 -4.65 -4.43

Mendus AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.07 48.14 -0.41
OSTO:IMMU
27GF Score
Mendus AB OSTO:IMMU
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mendus AB Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr47.66 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of kr47.66 Mil mean?
Mendus AB (OSTO:IMMU) has a Other Financing of kr47.66 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Mendus AB and its competitors.
Is Mendus AB's Other Financing too high?
Mendus AB's current Other Financing is kr47.66 Mil. Overall, Mendus AB has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Mendus AB's Other Financing compare to VRTX and REGN?
Mendus AB's Other Financing of kr47.66 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Mendus AB and its competitors. Mendus AB's current Other Financing is kr47.66 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mendus AB stock overvalued right now?
Mendus AB (OSTO:IMMU) has a current Other Financing of kr47.66 Mil. The current Other Financing is kr47.66 Mil. Mendus AB's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Mendus AB (OSTO:IMMU), the current Other Financing is kr47.66 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mendus AB Business Description

Other Exchanges 1YG0:Germany
Address Vastra Tradgardsgatan 15, Stockholm, SWE, 11153
Mendus AB is a clinical-level biopharmaceutical company based on the company's allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. Its operations consist of research and development for pharmaceuticals. The company's Pipeline includes: Vididencel, and Ilixadencel.
27GF Score

Get the complete analysis for OSTO:IMMU

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr6.11
Price